LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

Начало・Списък с акции・Becton Dickinson and Co

Becton Dickinson and Co

Затворен

Сектор Здравеопазване

232.6 -0.17

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

232.41

Максимум

233.91

Ключови измерители
By Trading Economics
Приходи	-50M 487M
Продажби	10M 5.1B
P/E Средно за сектора	50.04 103.001
EPS	3.5
Марж на печалбата	9.625
Служители	73,000
EBITDA	-124M 1.2B

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+20.64 upside

Дивиденти
By Dow Jones
Следващи печалби	7.11.2024 г.
Следваща дата на дивидент	30.09.2024 г.
Следваща дата на екс-дивидент	9.09.2024 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	70B
Предишно отваряне	232.77
Предишно затваряне	232.6

Настроения в новините

By Acuity

91%

8 / 365 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

N/A / 236.38 Подкрепа & съпротива

Becton Dickinson and Co Графика

Свързани новини

1.08.2024 г., 11:08 ч. UTC

Печалби

Becton 3Q Adjusted Earnings Top Views But International Sales Weigh on FY24 Outlook

3.06.2024 г., 11:18 ч. UTC

Придобивния, сливания и поглъщания

Becton Dickinson to Acquire Edwards Lifesciences' Critical Care Product Group for $4.2 Billion in Cash

2.05.2024 г., 11:07 ч. UTC

Печалби

Becton Dickinson Shakes Up 2024 Outlook After Growing 2Q Sales, Earnings

1.08.2024 г., 10:37 ч. UTC

Печалби

Becton Dickinson Now Sees FY24 Revenue About $20.1B; Had Seen $20.1B-$20.3B >BDX

1.08.2024 г., 10:35 ч. UTC

Печалби

Becton Dickinson Sees FY24 Revenue Up About 3.7%, Organic Revenue Up 5%-5.25% >BDX

1.08.2024 г., 10:35 ч. UTC

Печалби

Becton Dickinson Sees FY24 Adj EPS $13.05-Adj EPS $13.15 >BDX

1.08.2024 г., 10:30 ч. UTC

Печалби

Becton Dickinson 3Q EPS $1.68 >BDX

1.08.2024 г., 10:30 ч. UTC

Печалби

Becton Dickinson 3Q Net $487M >BDX

1.08.2024 г., 10:30 ч. UTC

Печалби

Becton Dickinson 3Q Adj EPS $3.50 >BDX

1.08.2024 г., 10:30 ч. UTC

Печалби

Becton Dickinson 3Q Rev $5B >BDX

4.06.2024 г., 17:26 ч. UTC

Придобивния, сливания и поглъщания

Edwards Lifesciences Deal A Clear Win For Becton Dickinson, Analysts Say -- Analysis

3.06.2024 г., 15:30 ч. UTC

Горещи акции

Stocks to Watch Monday: GameStop, AMC, Paramount, Nvidia -- WSJ

3.06.2024 г., 13:26 ч. UTC

Придобивния, сливания и поглъщания

Edwards Lifesciences Stock Nears Breakout On A Surprise $4.2 Billion Deal -- IBD

3.06.2024 г., 12:25 ч. UTC

Топ новини

Придобивния, сливания и поглъщания

Becton Dickinson to Acquire Edwards Lifesciences' Unit for $4.2 Billion in Cash -- Update

3.06.2024 г., 11:03 ч. UTC

Топ новини

Придобивния, сливания и поглъщания

Becton Dickinson to Acquire Edwards Lifesciences' Critical Care Product Group for $4.2B in Cash

3.06.2024 г., 10:40 ч. UTC

Придобивния, сливания и поглъщания

Edwards Lifesciences To Sell Its Critical Care Product Group For $4.2 Billion To Becton Dickinson -- MarketWatch

3.06.2024 г., 10:32 ч. UTC

Придобивния, сливания и поглъщания

Becton Dickinson: Acquired Business Has About 4,500 Employees >BDX EW

3.06.2024 г., 10:31 ч. UTC

Придобивния, сливания и поглъщания

Becton Dickinson: Acquired Business Generated More Than $900 Million Revenue in 2023 >BDX

3.06.2024 г., 10:31 ч. UTC

Придобивния, сливания и поглъщания

Becton Dickinson: Deal Expands Portfolio of Smart Connected Care Solutions >BDX EW

3.06.2024 г., 10:30 ч. UTC

Придобивния, сливания и поглъщания

Becton Dickinson to Buy Edwards Lifesciences Critical Care Product Group for $4.2 Billion >BDX EW

3.06.2024 г., 10:30 ч. UTC

Придобивния, сливания и поглъщания

BD To Acquire Edwards Lifesciences' Critical Care Product Group For $4.2 Billion To Expand Smart Connected Care Solutions And Become An Advanced Monitoring Technology Leader >BDX EW

2.05.2024 г., 10:35 ч. UTC

Печалби

Becton Dickinson Had Seen FY24 Adjusted EPS $12.82-$13.06 >BDX

2.05.2024 г., 10:34 ч. UTC

Печалби

Becton Dickinson Raises FY24 View To Adj EPS $12.95-Adj EPS $13.15 >BDX

2.05.2024 г., 10:34 ч. UTC

Печалби

Becton Dickinson Still Sees FY24 Organic Revenue Growth of 5.5%-6.25% >BDX

2.05.2024 г., 10:33 ч. UTC

Печалби

Becton Dickinson Had Seen FY24 Revenue $20.2B-$20.4B >BDX

2.05.2024 г., 10:33 ч. UTC

Печалби

Becton Dickinson Cuts FY24 View To Rev $20.1B-$20.3B >BDX

2.05.2024 г., 10:30 ч. UTC

Печалби

Becton Dickinson 2Q Net $537M >BDX

2.05.2024 г., 10:30 ч. UTC

Печалби

Becton Dickinson 2Q Adj EPS $3.17 >BDX

2.05.2024 г., 10:30 ч. UTC

Печалби

Becton Dickinson 2Q EPS $1.85 >BDX

2.05.2024 г., 10:30 ч. UTC

Печалби

Becton Dickinson 2Q Rev $5B >BDX

Сравнение с други в отрасъла

Ценова промяна

Becton Dickinson and Co Прогноза

Ценова цел

By TipRanks

20.64% нагоре

12-месечна прогноза

Среден 280.7 USD 20.64%

Висок 312 USD

Нисък 255 USD

Според 11 анализатори от Wall Street, предложили 12-месечна ценова цел за Becton Dickinson and Co през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

11 ratings

Купи

Задържане

Продай

Според 11 анализатори, дали борсови рейтинги на Becton Dickinson and Co през последните 3 месеца.

Техническа оценка

By Trading Central

N/A / 236.38Подкрепа & съпротива

Recent bearish events outweigh bullish events.

All events are bearish.

Настроение

By Acuity

8 / 365 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Becton Dickinson and Co

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through segments such as BD Medical, BD Life Sciences and BD Interventional. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings. BD Medical consists of various business units, including medication delivery solutions, medication management solutions, diabetes care and pharmaceutical systems. The BD Life Sciences segment provides products for the safe collection and transport of diagnostics specimens, and instruments and reagent systems to detect a range of infectious diseases, healthcare-associated infections and cancers. The BD Interventional segment provides vascular, urology, oncology and surgical specialty products.